Lupin gains on getting USFDA`s tentative nod for Tolvaptan Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 1154.60, up by 6.15 points or 0.54% from its previous closing of Rs. 1148.45 on the BSE.
The scrip opened at Rs. 1163.95 and has touched a high and low of Rs. 1165.30 and Rs. 1152.75 respectively. So far 12815 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1184.00 on 29-Sep-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1183.90 and Rs. 1142.90 respectively. The current market cap of the company is Rs. 52621.39 crore.
The promoters holding in the company stood at 47.07%, while Institutions and Non-Institutions held 43.30% and 9.64% respectively.
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Tolvaptan Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg to market a generic equivalent of Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Co. This product will be manufactured at Lupin’s Nagpur facility in India. Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of $287 million in the U.S. (IQVIA MAT August 2023).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
